Recurance · prevention of future deaths reports
Pre-inquest brief
The earlier warning
James Boland · 5 Nov 2024 · Alison Mutch, Manchester South
“Maintaining its classification as a Class B drug was likely to encourage others to start to use it or continue to use it under the false impression it is”
judiciary.uk/…/james-boland-prevention-of-future-deaths-report
What was promised
Stated action 1 · response to James Boland (5 Nov 2024) · stated timescale: none stated
“I intend to commission the ACMD to conduct an updated harms assessment of ketamine as part of the forthcoming three-year work programme commission cycle.”
What recurred
- 19 Aug 2025 · Gemma Weeks · Brendan Allen · Identical hazard · confidence 0.96 (high)
The clearest link, quoted from both reports:
Earlier · James Boland · 5 Nov 2024
“Maintaining its classification as a Class B drug was likely to encourage others to start to use it or continue to use it under the false impression it is”
Later · Gemma Weeks · 19 Aug 2025
“Ketamine's classification as a class B controlled drug may give an impression that the dangers associated with its use are reduced as compared with class A drugs.”
What happened next
No evidence found either way · stated action 1
“The ACMD published its updated harms assessment for ketamine in January 2026. Its report includes detailed information about the use and misuse”
Ketamine - House of Commons Library · commonslibrary.parliament.uk/research-briefings/cbp-10856
“The Advisory Council on the Misuse of Drugs (ACMD) has today (28 January 2026) published its updated harms assessment of ketamine.”
ACMD announces decision on the classification of ketamine · firstwordpharma.com/story/7085336
“Drugs (ACMD) is calling for evidence on ketamine use, harms and interventions to inform its recommendations to Government on policy and classification.”
Where next for UK Ketamine policy and law? | Transform · transformdrugs.org/…/where-next-for-uk-ketamine-policy-and-law
No evidence found does not mean the action did not happen.